Loading
A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients is a phase 3 interventional study registered as NCT00884273 by Ferring Pharmaceuticals, with 182 participants recorded, started 2009-08 and reaching its primary completion in 2011-03. Interventions recorded: Degarelix, Goserelin, Bicalutamide. Conditions recorded: Prostate Cancer.
Linked to the drug Degarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
182 enrolled.
SD 16.8; Figures from the ClinicalTrials.gov results section (first posted 2012-04-11), not from a publication · SD 17.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)primary | Degarelix 240 mg/80 mg | 82 | -37.2 milliliter | - | 0.36 | link |
| Goserelin (3.6 mg) + Bicalutamide (50 mg) | 97 | -39 milliliter |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ferring Pharmaceuticals, Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
Shares Ferring Pharmaceuticals, Degarelix, Prostate cancer and the tag pipeline.
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
Shares Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
Shares Degarelix, Bicalutamide, Prostate cancer and the tag pipeline.
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
Shares Ferring Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/